Author:
Guan Michael,Fanelli David,Verbeek Thomas,Warfield Dennis J.,Liu Henry
Publisher
Springer International Publishing
Reference69 articles.
1. Pichot C, Ghignone M, Quintin L. Dexmedetomidine and clonidine: from second- to first-line sedative agents in the critical care setting? J Intensive Care Med. 2012;27(4):219–37. https://doi.org/10.1177/0885066610396815.
2. Giovannitti JA Jr, Thoms SM, Crawford JJ. Alpha-2 adrenergic receptor agonists: a review of current clinical applications. Anesth Prog. 2015;62(1):31–9. https://doi.org/10.2344/0003-3006-62.1.31. PMCID: PMC4389556.
3. Millan MJ, Cussac D, Milligan G, et al. Antiparkinsonian agent piribedil displays antagonist properties at native, rat, and cloned, human alpha(2)-adrenoceptors: cellular and functional characterization. J Pharmacol Exp Ther. 2001;297(3):876–87. PMID 11356907
4. Buerkle H, Yaksh TL. Pharmacological evidence for different alpha 2-adrenergic receptor sites mediating analgesia and sedation in the rat. Br J Anaesth. 1998;81(2):208–15. https://doi.org/10.1093/bja/81.2.208.
5. Nelson LE, Lu J, Guo T, Saper CB, Franks NP, Maze M. The alpha2-adrenoceptor agonist dexmedetomidine converges on an endogenous sleep-promoting pathway to exert its sedative effects. Anesthesiology. 2003;98(2):428–36. https://doi.org/10.1097/00000542-200302000-00024.